Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProvexis Share News (PXS)

Share Price Information for Provexis (PXS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.65
Bid: 0.60
Ask: 0.70
Change: 0.00 (0.00%)
Spread: 0.10 (16.667%)
Open: 0.65
High: 0.00
Low: 0.00
Prev. Close: 0.65
PXS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Idox Surges On Dye & Durham Takeover Offer

Fri, 19th Feb 2021 11:23

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

----------

AIM - WINNERS

----------

Idox, up 17% at 72.00 pence, 12-month range 24.5p-79p. The management software provider says it received a possible cash offer from Toronto-based provider of cloud-based software Dye & Durham. Idox says the proposed price is 75 pence per Idox share. Idox currently has around 443.7 million shares in issue. Dye & Durham stresses that there "can be no certainty that an offer will be made".

----------

Focusrite, up 5.5% at 1,033.00p, 12-month range 335p-1,090p. The music and audio products group says demand has remained strong in the first half, leading to revenue expectations ahead of internal forecasts.

----------

Provexis, up 3.7% at 0.84p, 12-month range 0.36p-1.49p. The food technology company says it has raised GBP50,000 through the placing of 6.7 million shares at 0.75p each. Says it will use the total amount raised to support its international growth plans as it highlighted a new production run for its Fruitflow+ Omega-3 heart-health dietary supplement product is in the process of being commissioned.

----------

Fiske, up 1.6% at 66p, 12-month range 56p-70p. The stockbroker says its results for the half year show a marked improvement on the prior year. Revenue for the six months to the end of November 2020 grew by 11% year-on-year to GBP2.8 million. Fiske's commission revenue was up 5% on the prior year, while its investment management fees increased by 14%.

----------

Fevertree Drinks, up 0.9% at 2,398.00p, 12-month range, 888.4p-2,587p. UBS starts coverage on the tonic water maker at Buy. Fevertree is one of the biggest companies on AIM with a market value of GBP2.8 billion.

----------

AIM - LOSERS

----------

Horizonte Minerals, down 7.5% at 8.56p. The Brazil-focused nickel development firm says it raised around GBP18 million via the placing of 162.7 million shares at a price of 7.5p per placing share. The proceeds will be used to initiate specific early works and advance long-lead time items linked to the start of construction of the company's Araguaia ferro-nickel project in Brazil.

----------

Jangada Mines, down 6.3% at 9.60p, 12-month range 0.9p-12.44p. The natural resource company says it raised GBP1.3 million via a placing of 13.9 million shares at 9.0p each, which will allow it to continue development at its Brazilian vanadiam project.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
3 Dec 2009 08:49

Small caps round-up: Landore Resources, TXO, Aortech...

Shares in Landore Resources jumped after the Canadian miner said it made a 'significant gold discovery' in its Junior Lake property in the province of Ontario. Shares in Texas-focused oil and gas firm TXO slumped after it said oil production in the six months to September 30 fell to 13,221 barrels

Read more
3 Nov 2009 12:16

Small cap round-up: Provexis, Puricore, Sirius, Sopheon, Spiritel

Food technology group Provexis says it has been told that the European Commission review into the health claim wording for its Fruitflow anti-thrombatic technology for use on consumer products is now in "an advanced stage". Puricore's third quarter sales rose 25% to $10.8m, with the nine month tot

Read more
11 Aug 2009 09:30

Provexis surges on Crohn's disease trial

Provexis, the life-science business, has begun a clinical trial for its NSP#3G plantain medical food for Crohn's disease patients. "With the trial now starting and combined with recently obtained healthy human data, the Company will now commence seeking to identify potential global license or co-de

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.